This study provides support for reflex tumour testing with a comprehensive NGS panel that includes BRCA1/2 and other HR genes in order to determine treatment eligibility and aid in triaging patients for germline testing and genetic counselling referrals. This evidence concerns the gene BRCA1 and neoplasm.